secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-045791
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Biosciences reports Q1 net loss of $18.2M; plans Phase 1 combo trial with resmetirom in 2H 2025
--------------------------------------------------------------------------------

- Q1 net loss $18.2M (vs $6.6M Q1 2024); R&D expense $15.3M (vs $5.3M). Cash $144.6M.
- Phase 1 PK trial of denifanstat + resmetirom expected to start 2H 2025; data readout 1H 2026.
- End-of-Phase 2 FDA interaction completed Oct 2024; Phase 3 deferred until sufficient funding secured.
- Board changes: George Kemble to non-executive Chair; Beth Seidenberg appointed Lead Independent Director; Merdad Parsey to step off June 9, 2025.
- License partner Ascletis completed enrollment of 480-patient Phase 3 acne trial in China; topline results expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/0001104659-25-045791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer